申请人:Pfizer Inc.
公开号:US04572909A1
公开(公告)日:1986-02-25
A dihydropyridine compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein Y is --(CH.sub.2).sub.2 --, --(CH.sub.2).sub.3 --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --; R is aryl or heteroaryl; R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl; and R.sup.3 is hydrogen, C.sub.1 -C.sub.4 alkyl, 2-(C.sub.1 -C.sub.4 alkoxy)ethyl, cyclopropylmethyl, benzyl, or --(CH.sub.2).sub.m COR.sup.4 where m is 1, 2 or 3 and R.sup.4 is hydroxy, C.sub.1 -C.sub.4 alkoxy or --NR.sup.5 R.sup.6 where R.sup.5 and R.sup.6 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl can be employed for treating or preventing a heart condition or hypertension.
一种二氢吡啶化合物,其化学式为##STR1##或其药学上可接受的酸盐,其中Y为--(CH.sub.2).sub.2 --、--(CH.sub.2).sub.3 --、--CH.sub.2 CH(CH.sub.3)--或--CH.sub.2 C(CH.sub.3).sub.2 --;R为芳基或杂环芳基;R.sup.1和R.sup.2各自独立地为C.sub.1 -C.sub.4烷基或2-甲氧乙基;R.sup.3为氢、C.sub.1 -C.sub.4烷基、2-(C.sub.1 -C.sub.4烷氧基)乙基、环丙基甲基、苄基,或--(CH.sub.2).sub.m COR.sup.4,其中m为1、2或3,R.sup.4为羟基、C.sub.1 -C.sub.4烷氧基或--NR.sup.5 R.sup.6,其中R.sup.5和R.sup.6各自独立地为氢或C.sub.1 -C.sub.4烷基,可用于治疗或预防心脏病或高血压。